

Ref: Syn/Acts/CS/SE/BSE/NSE

Syngene International Limited

Biocon Park SEZ, Bommasandra IV Phase
Jigani Link Road, Bangalore 560099, India
T +91 80 6775 8000
F +91 80 6775 8808
CIN: L85110KA1993PLC014937

www.syngeneintl.com

January 25, 2017

To, The Manager Listing BSE Limited Corporate Relationship Department Dalal Street, Mumbai – 400 001	To, The Manager Listing National Stock Exchange of India Limited Corporate Communication Department Bandra (EAST), Mumbai – 400 051
Scrip Code: 539268	Scrip Symbol: SYNGENE

Dear Sir/Madam,

Subject: Appointment of Dr. Vijay Kuchroo as Additional Independent Director

Pursuant to the provisions of regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that based on the recommendation of Nomination and Remuneration Committee, the Board of Directors at its meeting held on January 24, 2017, has approved the appointment of Dr. Vijay Kuchroo as an Additional Director (Non-Executive, Independent) on Board of the Company effective from March 1, 2017 to hold office up to the date of next Annual General Meeting, wherein his appointment as an Independent Director will be placed before the members for their approval.

The brief profile of Dr. Vijay Kuchroo is enclosed.

This intimation will also be available on website of the Company www.syngeneintl.com.

This is for your information and record.

Thanking You,

Yours faithfully,

For SYNGENE INTERNATIONAL LIMITED

MAYANK VERMA
Digitally signed by MAYANK VERMA
DN: c=IN, o=Personal,
postalCode=560017, st=Karnataka,
2.5.4.20=f2285a34b8327771be6658c9
9862ec32c2dfeff81326ff8596b429caa8
83b64,
serialNumber=c1954b77eae2d96c42
001d566b09ccce91dab37b4b21c3d
23c8be013ac5fb, cn=MAYANK VERMA
Date: 2017.01.25 15:37:37 +05'30'

Mayank Verma

Company Secretary

E: Mayank.verma@syngeneintl.com

M: +91 97399 04949

T: + 91 80 6775 8781

PROFILE



Dr. Vijay K Kuchroo, 61 years, is the Samuel L. Wasserstrom Professor of Neurology at Harvard Medical School, Senior Scientist at Brigham and Women's Hospital and Co-Director of the Center for Infection and Immunity, Brigham Research Institutes, Boston. He is also an Associate Member of the Broad Institute and a participant in a Klarman Cell Observatory project that focuses on T cell differentiation. He is also the Director of the newly formed Evergrande Centre for Immunologic Diseases at Harvard Medical School and Brigham and Women's Hospital.

To his credit, Dr. Kuchroo first described the inhibitory receptor TIM-3, which is being exploited as a target for cancer immunotherapy. He was the first to describe the development of highly pathogenic Th17 cells, which has been shown to induce multiple different autoimmune diseases in humans. He has published over 325 original research papers in the field of Immunology and a paper describing development of Th17 authored by him has been one of the highest cited papers in Immunology. In addition, he has 25 patents and has founded 5 different biotech companies including CoStim Pharmaceuticals and Tempero Pharmaceuticals.

He is also an Independent, Non-Executive Director on the Board of Biocon Limited. He also serves on the scientific advisory Boards and works in advisory capacity to a number of big pharmaceutical companies including Pfizer, Novartis and Glaxo-Smith-Kline (GSK).